BioMarin Voxzogo trial demonstrates positive outcomes, potentially expanding its use amid increased competition.
Browsing: Clinical Trials & R&D
Latest clinical trial results, R&D progress, study updates, and global pharma research insights.
CellCentric raises $220M to advance its multiple myeloma drug through Phase 2 and Phase 3 trials, aiming to address persistent disease.
Cytokinetics Myqorzo trial demonstrates success in non-obstructive hypertrophic cardiomyopathy, potentially opening a multibillion-dollar market.
Vir Astellas T Cell Engager shows promise in oncology, with early data validating Vir’s shift from infectious diseases.
Bayer Asundexian Stroke Prevention shows a 26% risk reduction in Phase 3 trial, boosting its commercial outlook.
AstraZeneca China investment of $15B aims to enhance drug research and development capabilities.
Alveus obesity drug secures $160M to advance into Phase 2 testing, targeting amylin and GLP-1 pathways.
Alumis TYK2 psoriasis drug shows promise with Phase 3 results, doubling shares and competing with Takeda and Johnson & Johnson.
Merck ADC trial hold affects small cell lung cancer study, with FDA citing higher than anticipated deaths.
Galapagos TYK2 drug GLPG3667 succeeds in dermatomyositis trial but misses in lupus study, impacting future partnerships.